NDTV Profit-Latest Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables By चन्द्र कुमार अधिकारी Sunday, November 6, 2022 Comment Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses. from NDTV Profit-Latest https://ift.tt/726GaeF Related PostsSensex Rises 145 Points In Early Trade After 2 Days Of DeclineJio Financial Services Hit 5% Lower Circuit On Its Maiden Trading DayJio Financial Services Shares Hit Lower Circuit In Debut TradeTata Power Shares In Focus As Subsidiary Signs Deal With Tata Motors For Solar Project
0 Response to "Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables"
Post a Comment